<DOC>
<DOCNO>
EP-0003560
</DOCNO>
<TEXT>
<DATE>
19790822
</DATE>
<IPC-CLASSIFICATIONS>
C07D-405/06 A61K-31/55 C07D-319/00 A61K-31/495 C07D-409/00 A61K-31/535 A61K-31/415 A61K-31/519 C07D-233/60 C07C-17/16 A61P-7/00 C07D-403/00 C07D-405/00 C07D-233/84 C07C-17/00 A61K-31/44 C07D-233/56 <main>C07D-233/56</main> C07D-409/06 C07D-233/58 C07D-401/06 C07D-521/00 A61K-31/445 C07D-401/00 C07D-403/06 C07D-233/00 A61K-31/505 A61K-31/485 C07D-319/20 A61K-31/52 
</IPC-CLASSIFICATIONS>
<TITLE>
imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations.
</TITLE>
<APPLICANT>
wellcome foundgb<sep>the wellcome foundation limited<sep>the wellcome foundation limitedunicorn house 160 euston road p.o. box 129london nw1 2bpgb<sep>the wellcome foundation limited<sep>
</APPLICANT>
<INVENTOR>
thorogood peter brian<sep>thorogood, peter brian<sep>thorogood, peter brian114 venner roadsydenham london, s.e. 26gb<sep>thorogood, peter brian<sep>thorogood, peter brian114 venner roadsydenham london, s.e. 26gb<sep>
</INVENTOR>
<ABSTRACT>
pharmaceutical formulations comprising an imidazole  (or pharmaceutically acceptable salt thereof) of formula:    wherein   (i) a is an aliphatic hydrocarbon residue of from 1 to  4 carbon atoms and r is a naphthyl, tetrahydronaphthyl,  heterocyclyl, arylthio, arylalkylthio, aryloxy, arylalkyloxy,  arylhydroxymethylene, arylcarbonyl, arylalkylcarbonyl, alkyloxy,  alkylthio or a substituted cycloalkyl or cycloalkenyl  group or   (ii) a is a -soâ‚‚- group and r is aryl or heterocyclyl  or   (iii) a is a chemical bond and r is a heterocyclyl or  substituted phenyl group, or   (iv) a is an aliphatic hydrocarbon residue of from 1  to 3 carbon atoms and r is a halophenyl group.  some of these imidazoles and salts are novel.  methods of preparing the imidazoles are disclosed.   the imidazoles and their salts are useful in the treatment or  prophylaxis of thrombo-embolic conditions.  
</ABSTRACT>
</TEXT>
</DOC>
